

Research Article

Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer

Hongshuo Shi ¹, Sisheng Tian,² and Hu Tian ³

¹College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

²School of Management, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

³College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China

Correspondence should be addressed to Hu Tian; sdzydxth@163.com

Received 7 April 2020; Revised 3 January 2021; Accepted 21 January 2021; Published 20 February 2021

Academic Editor: George B. Lenon

Copyright © 2021 Hongshuo Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are “deficiency, dampness, stasis, and toxin,” and Fuzheng–Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in the treatment of CRC and also explain from a scientific point of view that FJD multidrug combination can resist “deficiency, dampness, stasis, and toxin.” **Methods.** We get the composition of FJD from the TCMSP database and get its potential target. We also get the potential target of colorectal cancer according to the OMIM Database, TTD Database, GeneCards Database, CTD Database, DrugBank Database, and DisGeNET Database. Subsequently, PPI analysis, KEGG pathways analysis, and GO biological processes analysis were carried out for the target of FJD in the therapy of colorectal cancer. In addition, we have also built a relevant network diagram. **Results.** In this study, we identified four core compounds of FJD in the therapy of colorectal cancer, including quercetin, kaempferol, beta-sitosterol, and stigmasterol. At the same time, we also obtained 30 core targets, including STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. FJD treatment of colorectal cancer mainly involves 112 KEGG pathways, including FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, 330 GO biological processes were summarized, including cell proliferation, cell apoptosis, angiogenesis, inflammation, and immune. **Conclusions.** In this study, we found that FJD can regulate cell proliferation, apoptosis, inflammation and immunity, and angiogenesis through PI3K-Akt signaling pathway to play an anti-CRC effect.

1. Introduction

Colorectal cancer (CRC), as the third most common cancer in the world, accounts for the fourth highest cancer mortality rate in the world [1]. It is a common malignant tumor of the digestive tract. Most patients' colorectal cancer is caused by their old age and unhealthy lifestyle, and only a few of them are caused by genetic factors. Other causes of colorectal cancer may include chronic inflammation of the gut, overweight, smoking, excessive intake of processed foods, and inadequate exercise [2]. In the diagnosis, due to the lack of effective clinical screening biomarkers, early symptoms of CRC are difficult to find. 15 to 25 percent of colorectal cancer patients have had liver metastasis at the time of detection,

while 15 to 25 percent of CRC patients will be found with liver metastasis after radical surgery [3, 4]. At present, the main treatment methods for CRC include radiotherapy and chemotherapy, surgery, targeting, and immunotherapy [5, 6]. Because of its limitations, these treatments present the whole body toxicity, drug resistance, low selectivity, low efficacy, and other adverse reactions [7]. Therefore, we want to find a more effective and less toxic method against CRC [8].

Herbal medicine and traditional medical practice have been reported as a world upsurge by the World Health Organization's global Atlas of traditional, complementary, and alternative medicine [9]. Traditional Chinese medicine (TCM) has been used by the Chinese for thousands of years.

It is a part of Oriental traditional medicine. It not only has the characteristics of good curative effect and small side effects but also has the overall and systematic philosophy [10]. Chinese herbal medicine treatment can control tumor growth, improve immune function, regulate tumor micro-environment, and play a significant role in preventing cancer relapse and transfer.

There are four main factors in TCM Syndromes of colorectal cancer: “deficiency, dampness, stasis, and toxin” [11]. According to the contemporary Chinese medicine masters, the treatment of tumors should be combined with tonifying deficiency and resisting evil [12]. In the early stage, we analyzed the literature and data mining of the experience of five batches of national famous experts in traditional Chinese medicine (500 in each batch, 3000 in total) and three sessions of Chinese Medicine Masters (30 students each, a total of 90 people) in the treatment of CRC. At the same time, we found the combination of the Fuzheng–Jiedu Decoction (FJD). FJD consists of *Panax ginseng* C.A. Mey (“RenShen” in Chinese, RS), *Pinellia ternata* (“BanXia” in Chinese, BX), and *Smilacis Glabrae Rhizoma* (“TuFuLing” in Chinese, TFL). Not only does the drug combination have a good antitumor effect, but also it can improve the symptoms of CRC such as asthenia and abdominal distension [13]. Based on the theory of TCM, the compatibility of FJD can not only treat “deficiency, dampness, stasis, and toxin” but also have mild efficacy and strong synergistic effect. RS can treat deficiency and improve immunity and antitumor, and BX and TFL can treat toxin, stasis, and dampness. Ginsenosides (TGCG) in RS guide generation cycle retardant and apoptosis in HT-29 cells [14]. BX can inhibit the hyperplasia of tumor cells, cut down the expression of tumor proteins, induce apoptosis of tumor cells, and act on multiple organ tumor cells [15]. Various compounds isolated from TFL have been proved to hold up the growth and hyperplasia of CRC cells in varying degrees [16]. Although the pharmacological research of RS, BX, TFL, and their monomers has made some achievements, the traditional pharmacological evaluation method is difficult to analyze the complex mechanism of FJD synergistic treatment of CRC. Therefore, this study through the network pharmacology elaborated its mechanism of action, hoping to provide the theoretical basis for the compatibility of TCM and provide more methods for the treatment of CRC.

Network pharmacology is an effective new strategy integrating bioinformatics, chemical informatics, network biology, traditional pharmacology, and network analysis [17]. Network pharmacology, according to the model of “gene-target-disease,” systematically discusses the relationship between medicine and diseases, which accords with the holistic view of TCM theory [18]. In order to reveal the natural active compounds and potential mechanisms of traditional Chinese medicine prescriptions from a systematic and holistic perspective, network pharmacology provides a new method for them [19]. The goal of this study was to identify the natural compounds of FJD by network pharmacology and to explore the key target of FJD in the treatment of colorectal cancer, so as to comprehend its potential mechanism of action. Our plan is the expression in Figure 1.

2. Materials and Methods

2.1. Collection of Compounds in FJD. The compounds of RS, BX, and TFL in FJD were extracted from the TCM systems pharmacology (TCMSP) database. TCMSP database is one of the most comprehensive databases of Chinese herbal medicine, which is used to find the relationship among herbs, natural compounds, target protein, and diseases [20].

2.2. Screening of the Active Ingredients in FJD. Although FJD is composed of many natural compounds, only a few of them have pharmacological effects. Therefore, it is necessary to screen the pharmacokinetics of each compound of Chinese herbal medicine [21]. Based on the previously reported model, we screened various compounds in FJD according to the pharmacokinetic absorption (A), distribution (D), metabolism (M), and excretion (E) parameters. Based on the previous literature and the information in the relevant Chinese herbal medicine database, we selected natural compounds with oral bioavailability (OB) greater or equal to 30 percent and drug sensitivity (DL) greater or equal to 0.18 for further analysis [22] (Supplementary file 1).

2.3. Get the Target Protein of the Selected Compounds. All the active ingredients were input into the TCM systems pharmacology (TCMSP) database to get the known targets. The 2D structure of the compounds obtained from PubChem was imported into the SwissTargetPrediction database, and a threshold (probability >0.6) was set to obtain more credible targets for each compound.

2.4. Search Targets of CRC. We collected the CRC targets from six resources: (1) Online Mendelian Inheritance in Man database (OMIM); (2) Therapeutic Target Database (TTD); (3) GeneCards Human Gene database (score ≥ 30); (4) Comparative Toxicogenomics Database (CTD); (5) DrugBank Database; and (6) DisGeNET Database (Score_gda ≥ 0.3). The official names of the genes (FJD and CRC) were obtained as UniProt, and the species was selected as “Homo sapiens.” Then, the names of the targets were uniformly converted into gene and UniProt ID [23]. Finally, we map the target genes of FJD active constituent and CRC related target genes, and screen the coincident target genes as the related targets of FJD treatment for colorectal cancer.

2.5. PPI Network of Target Protein Interaction. The target gene of FJD for CRC was input into the STRING database, and its amplification and prediction were carried out. The network diagram of the target protein interaction in vivo was obtained. We first amplified the target protein of FJD against CRC with the STRING database and then input it into Cytoscape software. We use the “analysis network” tool in Cytoscape to get the protein interaction network to obtain the relevant parameters. Based on the four parameters of “Degree,” “BetweennessCentrality,” “ClosenessCentrality,” and “Stress,” we do topology analysis on the PPI network to get hub nodes [24].




FIGURE 1: Flow chart of this network pharmacology research.

2.6. *Enrichment Analysis of GO and KEGG Pathway.* GO biological process analysis and KEGG pathway analysis are effective methods to explain the role of target genes [25]. We input related hub target genes of FJD treatment CRC into DAVID 6.8 (high throughput functional labeling

bioinformatics network platform) database for GO biological process analysis and KEGG pathway analysis and identified GO biological process with P less than or equal to 0.01 and KEGG pathway with P less than or equal to 0.01.

2.7. Construction of a Network of Herbs, Nature Compounds, Targets, and Pathways. On the basis of the compounds, targets, and pathways of FJD in the treatment of colorectal cancer, combined with the functions of Cytoscape 3.7.1 software, a network model of herbs, ingredients, targets, and diseases was constructed. According to this network model, we made a scientific analysis of the relationship between herbs, ingredients, targets, and diseases. We constructed (1) “compound-target” network diagram; (2) “herbal-compound-target” network diagram; (3) PPI network diagram of FJD potential targets for CRC; and (4) “pathway-target” network diagram. Nodes in the network diagram are linked by edges, and these nodes can represent herbs, compounds, targets, and KEGG pathways.

3. Results

3.1. Preparation by the Screening of the Natural Active Ingredients in FJD. According to the TCMSP database, there are 202, 123, and 78 compounds in FJD, respectively. These compounds were screened by OB greater than or equal to 30 percent and DL greater than or equal to 0.18. After filtering and deduplicating values, 46 potential compounds were included. There are 22, 13, and 15 compounds in RS, BX, and TFL, respectively. The composition screening diagram is shown in Figure 2. Among the 46 selected compounds, stigmaterol and beta-sitosterol were found in RS, BX, and TFL.

3.2. Study on the Target of Effective Compounds of FJD. In this process, we screened 46 active compounds according to chemical similarity and got 212 related targets, including RS 128, BX 91, and TFL 188. As shown in Figure 3, we have established a “compound-target” network diagram composed of 252 nodes and 842 edges. We use the “analysis network” tool in Cytoscape to get the “Degree” parameter of the network, and we discover that the top four compounds of degree are quercetin (degree = 146), kaempferol (degree = 75), beta-sitosterol (degree = 51), and stigmaterol (degree = 45) (Table 1). As shown in Figure 4, we also built a “herbal-compound-target” network diagram composed of 256 nodes and 889 edges. Through this diagram, we can easily observe the relationship between herbs, ingredients, and targets and reveal the potential pharmacological effects of FJD. The conclusion of the network graph is consistent with the multitarget effect of Chinese herbal medicine and the synergistic effect of multidrug compatibility.

3.3. PPI Network Analysis. Through the method of multi-source database integration, the CRC target data in OMIM, TTD, GeneCards, CTD, DrugBank, and DisGeNET databases are integrated. A total of 1018 CRC targets were obtained according to the screening and removal of duplicate values. The intersection of FJD and CRC related targets was collected and 58 common targets were obtained as the related targets of FJD in CRC.

We input 58 target genes of FJD for colorectal cancer into the STRING database and got the PPI network diagram of 468




FIGURE 2: Column chart of composition screening.

nodes. The obtained targets are divided into two parts, including 468 targets (58 public targets and 410 other human protein targets), which may represent FJD in vivo response to CRC. There are nodes 468 and 12359 edges in total. Then, the topological characteristics of PPI are analyzed. We use the “analysis network” tool in Cytoscape to get the protein interaction network to obtain the relevant parameters, and based on the four parameters of “Degree,” “Betweenness-Centrality,” “ClosenessCentrality,” and “Stress,” the index above the median value is selected as the key index [26] (Figure 5) and the core nodes of FJD acting on CRC are obtained. The threshold value of the first screening is “Degree” ≥ 37.5 , “ClosenessCentrality” ≥ 0.481692 , “BetweennessCentrality” ≥ 0.000684 , and “Stress” ≥ 4828 . Then, through the topological analysis data screening again, 85 hub targets are obtained. The criteria for screening were “Degree” ≥ 62.5 , “ClosenessCentrality” ≥ 0.602967 , “BetweennessCentrality” ≥ 0.001387 , and “Stress” ≥ 1172 . We got 85 hub nodes and established the related network diagram. The network diagram (Figure 6) was composed of 85 nodes and 2698 edges. By analyzing the diagram, the top 30 targets are STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. These target genes (Table 2) may be the core targets of FJD in the treatment of CRC.

3.4. Enrichment Analysis of KEGG Pathway and GO Biological Process. After enrichment analysis of 85 hub targets by DAVID v6.8, we got 112 KEGG pathways and 330 GO biological processes according to $P < 0.01$.

3.4.1. KEGG Pathway Analysis. According to the P value, we selected the first 20 KEGG (Figure 7) pathways for analysis. KEGG pathways, mainly FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, we have constructed the network diagram between the first 20 KEGG pathways and 78 the targets. The network diagram (Figure 8) is composed of 98 nodes and 522 edges.




FIGURE 3: The “compound-target” network diagram of Fuzheng-Jiedu Decoction in the treatment.

TABLE 1: Compound information sheet.


Molecule ID	Molecule name	Structure	OB (%)	DL	Herb
Quercetin	MOL000098		46.43	0.28	TFL

TABLE 1: Continued.







Molecule ID	Molecule name	Structure	OB (%)	DL	Herb
Kaempferol	MOL000422		41.88	0.24	RS
Beta-sitosterol	MOL000358		36.91	0.75	RS, BX, and TFL
Stigmasterol	MOL000449		43.83	0.76	RS, BX, and TFL
Diosgenin	MOL000546		80.88	0.81	TFL
Ginsenoside rh2	MOL005344		36.32	0.56	RS

TABLE 1: Continued.

Molecule ID	Molecule name	Structure	OB (%)	DL	Herb
Baicalein	MOL002714		33.52	0.21	BX




FIGURE 4: The “herbal-compound-target” network diagram of Fuzheng–Jiedu Decoction in the treatment of colorectal cancer. Green represents herbs. Pink represents the compounds. Blue represents the targets.




FIGURE 5: The process of topological screening for the PPI network.




FIGURE 6: Construction of protein-protein interaction network expressed by hub target protein. 85 nodes represent 85 proteins, and 2698 edges represent the interaction between 2698 pairs of proteins. The node size and color represent the degree, and the data come from the string.

3.4.2. *Gene Ontology Analysis.* According to the *P* value, we selected the first 25 GO biological processes (Figure 9) for analysis, and the top 10 are (GO: 0008284) positive regulation of cell proliferation, (GO: 0043066) negative regulation of apoptotic process, (GO: 0045944) positive regulation of transcription from RNA polymerase II promoter, (GO: 0010628) positive regulation of gene expression, (GO: 0042493) response to drug, (GO: 0045893) positive regulation of transcription, (GO: 0045429) positive regulation of nitric oxide biosynthetic process, (GO: 0048015) phosphatidylinositol-mediated signaling, (GO: 0001934) positive regulation of protein phosphorylation, and (GO: 0038128) ERBB2 signaling pathway.

4. Discussion

As the third most common cancer, colorectal cancer patients are less likely to survive for more than five years, still less than 10% [25, 27]. Chinese herbal medicine has achieved an ideal curative effect in the treatment of tumors. However, it is difficult to explain the complex mechanism of the traditional method. Therefore, the integration of network pharmacology based on big data bioinformatics into the molecular mechanism of Chinese herbal medicine in the treatment of diseases is of great significance.

According to the network diagram of “compound-target,” we got 4 core compounds, namely, quercetin, kaempferol, baicalein, and beta-sitosterol. Quercetin is a

TABLE 2: Information on 30 core targets.

Gene	Description	UniProt	Degree	Source
STAT3	Signal transducer and activator of transcription 3	P40763	84	Predicted
INS	Insulin	P01308	84	Predicted
TP53	Cellular tumor antigen p53	P04637	84	Validated
VEGFA	Vascular endothelial growth factor A	P15692	83	Validated
AKT1	RAC-alpha serine/threonine-protein kinase	P31749	83	Predicted
TNF	Tumor necrosis factor	P01375	82	Validated
IL6	Interleukin-6	P05231	82	Validated
JUN	Transcription factor AP-1	P05412	81	Validated
EGF	Pro-epidermal growth factor	P01133	81	Validated
CASP3	Caspase-3	P42574	80	Predicted
MAPK3	Mitogen-activated protein kinase 3	P27361	79	Predicted
MAPK1	Mitogen-activated protein kinase 1	P28482	79	Validated
MAPK8	Mitogen-activated protein kinase 8	P45983	79	Validated
SRC	proto-oncogene tyrosine-protein kinase Src	P12931	78	Predicted
IGF1	Insulin-like growth factor I	P05019	78	Predicted
CCND1	G1/S-specific cyclin D1	P24385	78	Predicted
ESR1	Estrogen receptor	P03372	77	Validated
EGFR	Epidermal growth factor receptor	P00533	77	Validated
PTEN	Phosphatase and tensin homolog	P60484	76	Predicted
MTOR	Serine/threonine-protein kinase mTOR	P42345	75	Predicted
FOS	Proto-oncogene c-Fos	P01100	74	Predicted
PTGS2	Prostaglandin G/H synthase 2	P35354	73	Validated
CXCL8	Interleukin-8	P10145	73	Predicted
HRAS	GTPase HRas	P01112	73	Predicted
CDH1	Cadherin-1	P12830	73	Predicted
BCL2L1	Bcl-2-like protein 1	Q07817	72	Predicted
FN1	Fibronectin	P02751	71	Predicted
MMP9	Matrix metalloproteinase-9	P14780	71	Predicted
ERBB2	Receptor tyrosine-protein kinase erbB-2	P04626	70	Predicted
JAK2	Tyrosine-protein kinase JAK2	O60674	69	Predicted

kind of polyglycol hydroxyflavonoid widely existing in nature. It has many functions such as antitumor, anti-oxidation, anti-inflammatory, and immune regulation [28]. In vitro experiments have shown that quercetin used alone or in combination with other drugs can inhibit the development of CRC tumors by blocking the division cycle of cancer cells, reducing the biological activity of cancer cells, and regulating certain cancer-related signaling pathways [29]. Kaempferol exists in propolis, propolis tea, and vegetables. It is a common flavonoid in food. It has the effect of antiproliferation and inducing apoptosis of human colon cancer cells [30]. Beta-sitosterol is one of the most abundant phytosterols in the diet, comparable to animal cholesterol [31]. It has been reported that β -sitosterol can significantly inhibit the progression of DMH-induced CRC in mice [32]. Modern research shows that stigmasterol can destroy the formation of tumor blood vessels in vivo [33]. These compounds are the material basis of FJD acting on CRC.

According to the analysis of KEGG enrichment, FJD treatment of CRC may be achieved through multiple pathways, the most important of which may be PI3K/Akt single pathway. After enrichment analysis of KEGG pathways and GO biological process, we found that the potential mechanism of FJD in the treatment of CRC may be related to its participation in cell proliferation, cell apoptosis, inflammation and immune, and angiogenesis. Next, we will elaborate on these four aspects in combination with the core targets.

4.1. Cell Proliferation. PI3K/Akt signaling pathway is critical for the proliferation of colorectal cancer cells. Among them, PI3K/Akt is an important intracellular signaling pathway, which is closely related to the formation and progress of colorectal cancer. It can participate in cell growth, proliferation, differentiation, and migration. PI3K gene activation and PTEN inactivation common in CRC lead to Akt and overexpression of downstream targets, including PKC, promotes cell growth and rescues cells from apoptosis. Therefore, the inhibition of PI3K/Akt has been widely used to treat CRC [34, 35]. EGF binds with EGFR, thus activating the epidermal growth factor receptor, activating PI3K/Akt pathway, and finally promoting tumor proliferation [36, 37]. Jun transcription factor (JUN) is a key gene of the AP-1 family of transcription factor complexes. MiR-22 is considered to be an important tumor suppressor miRNAs [38, 39], which can significantly inhibit the ability of AP-1 to bind DNA [40]. According to reports, Jun can downregulate the expression of p53 (TP53), while p53 can activate the expression of miR-22 [41]. Some results show that the overexpression of proto-oncogenes in fibroblasts makes it easy for c-jun (JUN) to bind to cyclin D1 (CCND1), thereby activating the expression of cyclin D1 and promoting the cell cycle process [42]. Cell division cycle-associated protein 2 may target CCND1 by promoting PI3K/Akt pathway, thus promoting the abnormal proliferation of colorectal cancer cells [43]. IGF1 (insulin-like growth factor I) is a powerful




FIGURE 7: KEGG enrichment.

mitogenic factor in CRC cells and an important antiapoptotic factor in CRC cells. IGF1 can bind to its related receptor IGF1R to induce PI3K/Akt pathway. As we all know, the liver is the most common metastatic site of CRC. The source of IGF1 is the liver. Therefore, inhibiting IGF1R may be an effective method for the treatment of colorectal cancer [44].

Tumor cell proliferation plays a key role in the occurrence and development of human malignant tumors. Quercetin is derived from Chinese herbal medicine TFL, which can act on four targets: JUN, MAPK1, EGF, and EGFR. It may be the main compound of FJD to inhibit cancer cell proliferation. It has been reported that quercetin can inhibit proliferation and induce apoptosis of SW480, HCT116, HT 29, Caco-2, LoVo, and other CRC cells [45]. Also, baicalein (Table 1) can inhibit MAPK, Akt, or mTOR to hold up the abnormal proliferation of cancer cells.

4.2. Cell Apoptosis. Tumor suppressor p53 (TP53) can control the progression of cancer by inducing apoptosis,

upregulating DNA repair protein, and maintaining genome stability [46, 47]. At the same time, p53 mutants can activate the Akt signal to promote cancer cell invasion. Integrin and EGFR depend on the circulation of RCP to participate in this process [48]. In addition, in many cancers, including colorectal cancer, the expression of cyclooxygenase-2 (PTGS2) is out of control, while the expression of cyclooxygenase-2 is negatively regulated by p53 [49]. As an inhibitor, p53 inhibits the expression of some antiapoptotic genes, including Bcl-2 and promotes apoptosis [50]. Bcl-2 is an apoptotic inhibitor protein, and BCL2L1 belongs to Bcl-2 protein family [51]. Bax is an apoptotic protein, which can induce the formation of apoptotic bodies and upregulate the expression of Caspase-3 (CASP3). BCL2L1 can steady the chondriosome localization of Bax and make it lose its biological activity [52]. These proteins are the regulators of apoptosis in PI3K-Akt pathway [53]. It has been shown that CXCL8 has a negative correlation with the expression of Bcl-2-related cell death protein (BAD), thus inhibiting the




FIGURE 8: "Target-pathway" network. The yellow represents the core targets. The blue represents the other targets. The orange represents the related pathways.

apoptosis of colorectal cancer cells [54]. Besides, mir-204 may inhibit the expression of CXCL8 by inhibiting PI3K/Akt/mTOR pathway [55]. Also, the most important way FOXO participates in apoptosis is PI3K/Akt pathway, which triggers the expression of death receptor ligands such as TNF apoptosis ligand and Bcl-2 family members [56].

The disorder of apoptosis is directly or indirectly related to the occurrence of tumors [57]. In FJD, the compounds acting on TP53 are quercetin, baicalein, and diosgenin. The results show that baicalein can inhibit angiogenesis [58] and prevent tumor metastasis [59], and it can control the abnormal proliferation and cell cycle of cancer cells by inhibiting Ezrin and activating p53 pathway-related proteins [60]. Besides, a combination of kaempferol and 5-fluorouracil induces apoptosis through PI3K/Akt signaling pathway [61]. Studies show that quercetin-induced

apoptosis inhibits PI3K/Akt and apoptosis inhibitor Bcl-2, and the accumulation of HIF-1 α also has an inhibitory effect [62]. Diosgenin (Table 1) can upregulate p38 MAPK pathway-related proteins, thus promoting TRAIL (a member of the TNF cytokine family) induced apoptosis [63].

4.3. Inflammation and Immune. Patients with inflammatory bowel disease (IBD) including ulcerative colitis have a higher probability of developing colitis-related CRC [64]. During inflammation, immune cells can lead to the production of highly genotoxic oxygen/nitrogen-reactive substances, such as IL-6 and TNF- α [6], and form an inflammatory micro-environment. The production of these inflammatory factors is mediated through the following signaling pathways, such as signal transducers and transcription activator 3 (STAT3),




FIGURE 9: GO biological processes enrichment.

PI3K/AKT, cyclooxygenase-2 (PTGS2), and JAK/STAT. IL-6 binds to heterodimer receptors, thereby activating gp130 on the surface of cell membranes [65], activating and maintaining the phosphorylation level of STAT3, and promoting cell proliferation, migration, invasion, and antiapoptosis [66]. At the same time, TNF- α plays a biological role in tumor cells through the STAT3 signaling pathway, so the STAT3 signaling pathway is a bridge between inflammation and tumor [67]. PTGS2 encodes inducible prostaglandin synthase cyclooxygenase-2, which is an important rate-limiting enzyme produced by prostaglandins and has a key significance for malignant tumors. Activation of the PI3K/Akt signaling pathway can upregulate PTGS2 [68], which has been proved to be involved in the production of inflammatory prostaglandins through stimulation events and in various biological processes such as tumor cell proliferation, angiogenesis, and invasion [69]. T cell mediated acquired immunity can effectively promote the process of tumor regression. Tumor cells affect immune cells through the STAT3 signaling pathway and participate in the immune escape of tumor cells. Therefore, STAT3 has become an important protein in immunotherapy research [70]. IL-6 produced by

the tumor-bearing host can aggravate the immunosuppression in the tumor microenvironment by inhibiting antitumor cells including CD8 + T cells, thus leading to the metastasis and colonization of colon cancer cells [71].

Chronic inflammation is an important factor leading to CRC. TNF gene is regulated by quercetin, kaempferol, astilbin, and ginsenoside rh2 in FJD and IL6 gene is regulated by quercetin. Quercetin has a strong anti-inflammatory effect. It can reduce some special inflammatory factors including TNF- α , by preventing the phosphorylation and degradation of I κ B in the process of inflammation [72]. Studies have shown that ginsenoside rh2 (Table 1) upregulates the secretion levels of TNF- α and IL-6 in the serum of colon cancer mice, relieves tumor-related immunosuppression, and prolongs the survival of colon cancer mice [73].

4.4. Angiogenesis. VEGFA can induce angiogenesis by promoting the abnormal proliferation and migration of vascular endothelial cells, which is conducive to the growth, invasion, and metastasis of tumor [74]. Hypoxia is the feature of the tumor microenvironment. Cells under hypoxia

can produce hypoxia inducible factor-1 α (HIF-1 α), which can lead to the enhancement of tumor cell invasion and metastasis [35]. Under hypoxia state, VEGF enhanced expression and even the initial starting factor of angiogenesis in tumor tissue, while HIF-1 α played a “bridge” role in the process from hypoxia to VEGF increased expression [75]. Under the condition of hypoxia, it has also been found that HIF-1 α can also combine with the hypoxia response element (HRE) of hypoxia response gene, promote the transcription of the downstream target gene to enter the nucleus, promote Akt activation, activate PI3K/Akt signal transduction pathway, inhibit endothelial cell apoptosis, and promote angiogenesis [76].

As we all know, angiogenesis is a necessary condition and a key step for tumor growth and metastasis. Therefore, the inhibition of tumor angiogenesis can block the occurrence, development, invasion, and metastasis of tumors to a certain extent [77]. In FJD, the main compounds of genes that act on VEGFA are baicalein, diosgenin, and quercetin. Quercetin can inhibit tumor angiogenesis by inhibiting VEGFR2. Also, some studies have shown that kaempferol can inhibit the HIF-1 α and VEGFR2 in endothelial cells through PI3K/Akt/mTOR signals, thus showing its anti-angiogenesis ability [78].

5. Conclusion

Traditional Chinese medicine has been passed down for thousands of years in China. The idea of Chinese herbal medicine treating tumors is the combination of tonifying deficiency and resisting evil. Based on the combination of modern medicine, a lot of experience in treating malignant tumors has been summarized. In this study, we first recognized from the perspective of network pharmacology that FJD regulates cell proliferation, apoptosis, inflammation, immunity, and angiogenesis through the PI3K-Akt signaling pathway. In addition, we also provide a scientific explanation for FJD in treating “deficiency, dampness, stasis, and toxin,” and we hope to open a window for understanding the complex mechanism of action of Chinese herbal medicine and the essence of more concepts of traditional Chinese medicine.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request. The authors got the composition of FJD from the TCMSP database (<http://tcmssp.com/tcmsspsearch.php>) and its potential target from the TCMSP database (<http://tcmssp.com/tcmsspsearch.php>) and Swiss TargetPrediction database (<http://www.swisstargetprediction.ch/>). They also got the potential target of colorectal cancer according to the OMIM Database (<http://www.omim.org/>), TTD Database (<http://bidd.nus.edu.sg/group/cjttd/>), GeneCards Database, CTD Database (<http://ctdbase.org/>), DrugBank Database (<https://www.drugbank.ca/>), and DisGeNET Database (<http://www.disgenet.org/home/>). Subsequently, PPI analysis (STRING Database, <https://string-db.org/>), KEGG

pathways (DAVID Database, <https://david.ncicrf.gov/>) analysis, and GO biological processes (DAVID Database, <https://david.ncicrf.gov/>) analysis were carried out for the target of FJD in the therapy of colorectal cancer.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors' Contributions

Hongshuo Shi was responsible for the experimental operation and thesis writing. Sisheng Tian was responsible for the revision of the final version. Hu Tian proposed research ideas and designed research plans.

Acknowledgments

This project was supported by the Shandong Traditional Chinese Medicine Development Project (Z13508000022) and the AcShandong Traditional Chinese Medicine Inheritance and Development Project (Z13508000022), Network Pharmacology Interpretation of Fuzheng–Jiedu Decoction against Colorectal Cancer.

Supplementary Materials

Supplementary File 1 includes natural compounds contained in the Fuzheng–Jiedu Decoction (FJD), and the ADME parameter is oral bioavailability (OB) \geq 30% and drug-likeness (DL) \geq 0.18. Table (A) in Supplementary File 1 indicates the compounds in RS; Table (B) in Supplementary File 1 indicates the compounds in BX; and Table (C) in Supplementary File 1 indicates the compounds in TFL. (*Supplementary Materials*)

References

- [1] M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global patterns and trends in colorectal cancer incidence and mortality,” *Gut*, vol. 66, no. 4, pp. 683–691, 2016.
- [2] O. K. D. Stephen, “Diet, microorganisms and their metabolites, and colon cancer,” *Nature Reviews Gastroenterology & Hepatology*, vol. 13, no. 12, pp. 691–706, 2016.
- [3] E. J. Kuipers, W. M. Grady, D. Lieberman et al., “Colorectal cancer,” *Nature Reviews Disease Primers*, vol. 1, Article ID 15065, 2015.
- [4] H. Zhui, “The progress of TCM Research on liver metastasis of colorectal cancer,” *Hunan Journal of Traditional Chinese Medicine*, vol. 35, no. 12, pp. 129–133, 2019.
- [5] L. Faugeras, A. Dili, A. Druetz, B. Krug, C. Decoster, and L. D’Hondt, “Treatment options for metastatic colorectal cancer in patients with liver dysfunction due to malignancy,” *Critical Reviews in Oncology/Hematology*, vol. 115, pp. 59–66, 2017.
- [6] R. Francescone, V. Hou, and S. I. Grivennikov, “Cytokines, IBD, and colitis-associated cancer,” *Inflammatory Bowel Diseases*, vol. 21, no. 2, pp. 409–418, 2015.
- [7] F. Geng, Z. Wang, H. Yin, J. Yu, and B. Cao, “Molecular targeted drugs and treatment of colorectal cancer: recent

- progress and future perspectives,” *Cancer Biotherapy and Radiopharmaceuticals*, vol. 32, no. 5, pp. 149–160, 2017.
- [8] B. Gong, Y. Kao, C. Zhang, H. Zhao, F. Sun, and Z. Gong, “Exploring the pharmacological mechanism of the herb pair “HuangLian-GanJiang” against colorectal cancer based on network pharmacology,” *Evidence-based Complementary and Alternative Medicine*, vol. 2019, Article ID 2735050, 12 pages, 2019.
- [9] G. Bodeker and C.-K. Ong, *WHO Global Atlas of Traditional, Complementary and Alternative Medicine*, World Health Organization, Geneva, Switzerland, 2005.
- [10] G. Yu, W. Wang, X. Wang et al., “Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis,” *BMC Complementary and Alternative Medicine*, vol. 18, no. 1, p. 292, 2018.
- [11] D. Li, W. Wang, L. Xiang et al., “The type of Traditional Chinese Medicine syndrome predicts prognosis and chemotherapeutic outcomes in colorectal cancer,” *European Journal of Integrative Medicine*, vol. 33, 2020.
- [12] T. Hu and S. Tian, “Analysis of the experience of the first national medical master in the treatment of malignant tumors,” *Shi Zhen National Medicine*, vol. 30, no. 1, pp. 193–194, 2019.
- [13] T. Hu, *Periodical Literature Analysis of Contemporary Famous Chinese Medicine Experts in Diagnosis and Treatment of Colorectal Cancer and Summary of Tutor Experience*, Shandong University of traditional Chinese medicine, Jinan, China, 2020.
- [14] T. Li, W. Sun, X Dong et al., “Total ginsenosides of Chinese ginseng induces cell cycle arrest and apoptosis in colorectal carcinoma HT-29 cells,” *Oncology Letters*, vol. 16, no. 4, p. 4640, 2018.
- [15] X. Dong, W. Xu, J. Shen, and H. Sun, “Research and application of Pinellia Ternata in the treatment of malignant tumors,” *Journal of Traditional Chinese Medicine*, vol. 47, no. 4, pp. 106–108, 2019.
- [16] S. Hua, Y. Zhang, J. Liu et al., “Ethnomedicine, phytochemistry and pharmacology of smilax glabra: an important traditional Chinese medicine,” *The American Journal of Chinese Medicine*, vol. 46, pp. 261–297, 2018.
- [17] S. I. Berger and R. Iyengar, “Network analyses in systems pharmacology,” *Bioinformatics*, vol. 25, no. 19, pp. 2466–2472, 2009.
- [18] D. Bu, Z. Su, J. Zou, M. Meng, and C. Wang, “Study of the mechanism underlying therapeutic effect of compound Longmaining on myocardial infarction using a network pharmacology-based approach,” *Biomedicine & Pharmacotherapy*, vol. 118, 2019.
- [19] W. Song, S. Ni, Y. Fu, and Y. Wang, “Uncovering the mechanism of Maxing Ganshi Decoction on asthma from a systematic perspective: a network pharmacology study,” *Scientific Reports*, vol. 8, no. 1, 2018.
- [20] J. Ru, P. Li, J. Wang et al., “TCMSP: a database of systems pharmacology for drug discovery from herbal medicines,” *Journal of Cheminformatics*, vol. 6, no. 1, p. 13, 2014.
- [21] C. Ma, C. Zhai, X. Tian et al., “A systems pharmacology-based study of the molecular mechanisms of san cao decoction for treating hypertension,” *Evidence-based Complementary and Alternative Medicine*, vol. 2019, Article ID 3171420, 10 pages, 2019.
- [22] F. Tang, Q. Tang, Y. Tian, Q. Fan, Y. Huang, and X. Tan, “Network pharmacology-based prediction of the active ingredients and potential targets of Mahuang Fuzi Xixin decoction for application to allergic rhinitis,” *Journal of Ethnopharmacology*, vol. 176, no. Complete, pp. 402–412, 2015.
- [23] W. Wang, T. Liu, L. Yang et al., “Study on the multi-targets mechanism of triphala on cardio-cerebral vascular diseases based on network pharmacology,” *Biomedicine & Pharmacotherapy*, vol. 116, 2019.
- [24] S.-Y. Xiang, J. Zhao, Y. Lu et al., “Network pharmacology-based identification for therapeutic mechanism of Ling-Gui-Zhu-Gan decoction in the metabolic syndrome induced by antipsychotic drugs,” *Computers in Biology and Medicine*, vol. 110, p. 1, 2019.
- [25] R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics,” *A Cancer Journal for Clinicians*, vol. 63, no. 1, pp. 11–30, 2013.
- [26] Y. Wan, L. Xu, Z. Liu et al., “Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms,” *BMC Complementary and Alternative Medicine*, vol. 19, no. 1, 2019.
- [27] J. Chen, C. Li, Y. Zhu et al., “Integrating GO and KEGG terms to characterize and predict acute myeloid leukemia-related genes,” *Hematology*, vol. 20, no. 6, pp. 336–342, 2015.
- [28] S. G. Darband, M. Kaviani, B. Yousefi et al., “Quercetin: a functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer,” *Journal of Cellular Physiology*, vol. 233, no. 9, pp. 6544–6560, 2018.
- [29] P. Poyil, B. Amit, S. Young-Ok et al., “Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways,” *PLoS One*, vol. 7, no. 10, Article ID e47516, 2012.
- [30] S. Yao, X. Wang, C. Li, T. Zhao, H. Jin, and W. Fang, “Kaempferol inhibits cell proliferation and glycolysis in esophagus squamous cell carcinoma via targeting EGFR signaling pathway,” *Tumor Biology*, vol. 37, no. 8, pp. 10247–10256, 2016.
- [31] A. B. Awad and C. S. Fink, “Phytosterols as anticancer dietary components: evidence and mechanism of action,” *The Journal of Nutrition*, vol. 130, no. 9, pp. 2127–2130, 2000.
- [32] M. S. Bin Sayeed and S. S. Ameen, “Beta-sitosterol: a promising but orphan nutraceutical to fight against cancer,” *Nutrition and Cancer*, vol. 67, no. 8, pp. 1216–1222, 2015.
- [33] T. Kangsamaksin, S. Chaitongyot, C. Wootthichairangsan et al., “Lupeol and stigmasteryl suppress tumor angiogenesis and inhibit cholangiocarcinoma growth in mice via down-regulation of tumor necrosis factor- α ,” *PLoS One*, vol. 12, Article ID e0189628, 2017.
- [34] C. P. R. Xavier, C. F. Lima, A. Preto, R. Seruca, M. Fernandes-Ferreira, and C. Pereira-Wilson, “Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells,” *Cancer Letters*, vol. 281, no. 2, pp. 162–170, 2009.
- [35] Y. Kitajima, T. Ide, T. Ohtsuka, and K. Miyazaki, “Induction of hepatocyte growth factor activator gene expression under hypoxia activates the hepatocyte growth factor/c-Met system via hypoxia inducible factor-1 in pancreatic cancer,” *Cancer Science*, vol. 99, no. 7, pp. 1341–1347, 2008.
- [36] M. F. Rimawi, P. B. Shetty, H. L. Weiss et al., “Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes,” *Cancer*, vol. 116, no. 5, pp. 1234–1242, 2010.
- [37] J. A. Engelman, J. Luo, and L. C. Cantley, “The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism,” *Nature Reviews Genetics*, vol. 7, no. 8, pp. 606–619, 2006.

- [38] J. Xiong, "Emerging roles of MicroRNA-22 in human disease and normal physiology," *Current Molecular Medicine*, vol. 12, no. 3, pp. 247–258, 2012.
- [39] W. Yuan, Y. Li, M. Ding, H. Zhang, X. Xu, and J. Tang, "Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer," *International Journal of Oncology*, vol. 50, pp. 345–355, 2017.
- [40] J. Yang, L. Chen, J. Ding et al., "Cardioprotective effect of miRNA-22 on hypoxia/reoxygenation induced cardiomyocyte injury in neonatal rats," *Gene*, vol. 579, no. 1, pp. 17–22, 2015.
- [41] Y. Liu, X. Chen, R. Cheng et al., "The Jun/miR-22/HuR regulatory axis contributes to tumourigenesis in colorectal cancer," *Molecular Cancer*, vol. 17, no. 1, p. 11, 2018.
- [42] C. Zhang, C. Chang, H. Gao, Q. Wang, F. Zhang, and C. Xu, "MiR-429 regulates rat liver regeneration and hepatocyte proliferation by targeting JUN/MYC/BCL2/CCND1 signaling pathway," *Cellular Signalling*, vol. 50, 2018.
- [43] Y. Feng, W. Qian, Y. Zhang et al., "CDCA2 promotes the proliferation of colorectal cancer cells by activating the AKT/CCND1 pathway in vitro and in vivo," *BMC Cancer*, vol. 19, no. 1, 2019.
- [44] X. L. Chao, L. L. Wang, R. Liu, Y. Li, and X. J. Zhou, "Association between CA repeat polymorphism in IGF1 gene promoter and colorectal cancer risk in a native Chinese population," *Neoplasma*, vol. 66, no. 6, 2019.
- [45] X. Qiu and C. Ma, "Research progress of quercetin against colon cancer," *Chinese Journal of Traditional Chinese Medicine*, vol. 33, no. 10, pp. 2333–2335, 2015.
- [46] B. Jean-Christophe, S. Sylvanie, and M. P. Khoury, "Uncovering the role of p53 splice variants in human malignancy: a clinical perspective," *Onco Targets and Therapy*, vol. 7, pp. 57–68, 2013.
- [47] A. Ventura, D. G. Kirsch, M. E. McLaughlin et al., "Restoration of p53 function leads to tumour regression in vivo," *Nature*, vol. 445, no. 7128, pp. 661–665, 2007.
- [48] H. Li, J. Zhang, J. H. M. Tong et al., "Targeting the oncogenic p53 mutants in colorectal cancer and other solid tumors," *International Journal of Molecular Sciences*, vol. 20, no. 23, 2019.
- [49] A. K. Maurya and M. Vinayak, "Anticarcinogenic action of quercetin by downregulation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C (PKC) via induction of p53 in hepatocellular carcinoma (HepG2) cell line," *Molecular Biology Reports*, vol. 42, no. 9, pp. 1419–1429, 2015.
- [50] S. N. D. C. Pereira, M. C. Lima, T. B. Boquimpani et al., "Lycopene extracts from different tomato-based food products induce apoptosis in cultured human primary prostate cancer cells and regulate TP53, Bax and bcl-2 transcript expression," *Asian Pacific Journal of Cancer Prevention : APJCP*, vol. 18, no. 2, 2017.
- [51] Z. Yang, Y. An, N. Wang, X. Dong, and H. Kang, "LINC02595 promotes tumor progression in colorectal cancer by inhibiting miR-203b-3p activity and facilitating BCL2L1 expression," *Journal of Cellular Physiology*, vol. 235, pp. 7449–7464, 2020.
- [52] H. Zhang, Y. Zong, G. Qiu et al., "Silencing Lin28 promotes apoptosis in colorectal cancer cells by upregulating let-7c targeting of antiapoptotic BCL2L1," *Molecular Medicine Reports*, vol. 17, no. 4, 2018.
- [53] V. Duronio, "The life of a cell: apoptosis regulation by the PI3K/PKB pathway," *Biochemical Journal*, vol. 415, no. 3, pp. 333–344, 2008.
- [54] J. Li, Q. Liu, X. Huang et al., "Transcriptional profiling reveals the regulatory role of CXCL8 in promoting colorectal cancer," *Frontiers in Genetics*, vol. 10, 2019.
- [55] F. Shuai, B. Wang, and S. Dong, "MicroRNA-204 inhibits the growth and motility of colorectal cancer cells by down-regulation of CXCL8," *Oncology Research*, vol. 26, no. 8, p. 1295, 2018.
- [56] M. Farhan, H. Wang, U. Gaur, P. J. Little, J. Xu, and W. Zheng, "FOXO signaling pathways as therapeutic targets in cancer," *International Journal of Biological Sciences*, vol. 13, no. 7, p. 815, 2017.
- [57] Y. Wang, C. Chao, Y. Chun, H. Li, and Y. Yang, "Apoptosis of human colorectal cancer cells induced by 6-gingerol and its effect on Bax, BCL2, Caspase3 and PARP1 gene expression," *Modern Food Technology*, vol. 33, no. 11, pp. 7–15, 2017.
- [58] Z. He, B. Li, G. O. Rankin, Y. Rojanasakul, and Y. C. Chen, "Selecting bioactive phenolic compounds as potential agents to inhibit proliferation and VEGF expression in human ovarian cancer cells," *Oncology Letters*, vol. 9, no. 3, pp. 1444–1450, 2015.
- [59] R. R. Ramjiawan, A. W. Griffioen, and D. G. Duda, "Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?" *Angiogenesis*, vol. 20, no. 2, pp. 185–204, 2017.
- [60] Z. Chen, R. Hou, S. Gao, D. Song, and F. Ye, "Baicalein inhibits proliferation activity of human colorectal cancer cells HCT116 through downregulation of Ezrin," *Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology*, vol. 49, no. 5, 2018.
- [61] Q. Li, L. Wei, L. Shan, Y. Chen, J. Lin, and J. Peng, "Synergistic effect of kaempferol and 5-fluorouracil on the growth of colorectal cancer cells by regulating the PI3K/Akt signaling pathway," *Molecular Medicine Reports*, vol. 20, pp. 728–734, 2019.
- [62] L. B. Si, M. Z. Zhang, Q. Han et al., "Sensitization of keloid fibroblasts by quercetin through the PI3K/Akt pathway is dependent on regulation of HIF-1 α ," *American Journal of Translational Research*, vol. 10, no. 12, p. 4223, 2018.
- [63] C. Lepage, D. Y. Léger, J. Bertrand et al., "Diosgenin induces death receptor-5 through activation of p38 pathway and promotes TRAIL-induced apoptosis in colon cancer cells," *Cancer Letters*, vol. 301, no. 2, pp. 0–202, 2011.
- [64] C. Lucas, N. Barnich, and H. T. T. Nguyen, "Microbiota, inflammation and colorectal cancer," *International Journal of Molecular Sciences*, vol. 18, no. 6, p. 1310, 2017.
- [65] Y. Yu, W. Wang, S. Zhai, S. Dang, and M. Sun, "IL6 gene polymorphisms and susceptibility to colorectal cancer: a meta-analysis and review," *Molecular Biology Reports*, vol. 39, no. 8, pp. 8457–8463, 2012.
- [66] S. Doumas, J. C. Paterson, P. M. Norris et al., "Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in squamous cell carcinoma of the tongue: markers of nerve invasion?" *Oral and Maxillofacial Surgery*, vol. 19, no. 1, pp. 61–64, 2015.
- [67] R. Rosell, J. Bertran-Alamillo, M. A. Molina, and M. Taron, "IL-6/gp130/STAT3 signaling axis in cancer and the presence of in-frame gp130 somatic deletions in inflammatory hepatocellular tumors," *Future Oncology*, vol. 5, no. 3, pp. 305–308, 2009.
- [68] Z. Cao, L.-Z. Liu, D. A. Dixon, J. Z. Zheng, B. Chandran, and B.-H. Jiang, "Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells," *Cellular Signaling*, vol. 19, no. 7, pp. 1542–1553, 2007.

- [69] C. S. Williams, M. Mann, and R. N. Dubois, "The role of cyclooxygenases in inflammation, cancer, and development," *Oncogene*, vol. 18, no. 55, pp. 7908–7916, 1999.
- [70] J. Wang, F. Huang, C. Jiang, and P. Chi, "Silencing signal transducer and activator of transcription 3 (STAT3) and use of anti-programmed cell death-ligand 1 (PD-L1) antibody induces immune response and anti-tumor activity," *Medical Science Monitor*, vol. 26, Article ID e915854, 2020.
- [71] Y. Toyoshima, H. Kitamura, H. Xiang et al., "IL6 modulates the immune status of the tumor microenvironment to facilitate metastatic colonization of colorectal cancer cells," *Cancer Immunology Research*, vol. 7, no. 12, p. 1944, 2019.
- [72] A. Kordkheyli Vahid, K. Tarsi Abbas, M. Mohammad et al., "Effects of quercetin on microRNAs: a mechanistic review," *Journal of Cellular Biochemistry*, vol. 120, no. 8, pp. 12141–12155, 2019.
- [73] J. Wang, Y. Chen, C. Dai, Y. Shang, and J. Xie, "Ginsenoside Rh2 alleviates tumor-associated depression in a mouse model of colorectal carcinoma," *American Journal of Translational Research*, vol. 8, no. 5, pp. 2189–2195, 2016.
- [74] L. Zhou, D.-S. Wang, Q.-J. Li, W. Sun, Y. Zhang, and K.-F. Dou, "Downregulation of the Notch signaling pathway inhibits hepatocellular carcinoma cell invasion by inactivation of matrix metalloproteinase-2 and -9 and vascular endothelial growth factor," *Oncology Reports*, vol. 28, no. 3, pp. 874–882, 2012.
- [75] W. Li, M. Petrimpol, K. D. Molle, M. N. Hall, E. J. Battegay, and R. Humar, "Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2," *Circulation Research*, vol. 100, no. 1, p. 79, 2007.
- [76] V. V. Polosukhin, J. M. Cates, W. E. Lawson et al., "Hypoxia-inducible factor-1 signalling promotes goblet cell hyperplasia in airway epithelium," *The Journal of Pathology*, vol. 224, no. 2, pp. 203–211, 2011.
- [77] H. S. Choi, K. Lee, M. K. Kim et al., "DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis," *Oncotarget*, vol. 7, no. 16, pp. 21775–21785, 2016.
- [78] Gi D. Kim, "Kaempferol inhibits angiogenesis by suppressing HIF-1 α and VEGFR2 activation via ERK/p38 MAPK and PI3K/Akt/mTOR signaling pathways in endothelial cells," *Preventive Nutrition and Food Science*, vol. 22, no. 4, 2017.